Cathepsin G Induces Cell Aggregation of Human Breast Cancer MCF-7 Cells via a 2-Step Mechanism: Catalytic Site-Independent Binding to the Cell Surface and Enzymatic Activity-Dependent Induction of the Cell Aggregation

Mediators of Inflammation - Tập 2012 - Trang 1-13 - 2012
Riyo Morimoto‐Kamata1, Sei-ichiro Mizoguchi1, Takeo Ichisugi1, Satoru Yui1
1Laboratory of Host Defense, Department of Pharma-Sciences, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Tóm tắt

Neutrophils often invade various tumor tissues and affect tumor progression and metastasis. Cathepsin G (CG) is a serine protease secreted from activated neutrophils. Previously, we have shown that CG induces the formation of E-cadherin-mediated multicellular spheroids of human breast cancer MCF-7 cells; however, the molecular mechanisms involved in this process are unknown. In this study, we investigated whether CG required its enzymatic activity to induce MCF-7 cell aggregation. The cell aggregation-inducing activity of CG was inhibited by pretreatment of CG with the serine protease inhibitors chymostatin and phenylmethylsulfonyl fluoride. In addition, an enzymatically inactive S195G (chymotrypsinogen numbering) CG did not induce cell aggregation. Furthermore, CG specifically bound to the cell surface of MCF-7 cells via a catalytic site-independent mechanism because the binding was not affected by pretreatment of CG with serine protease inhibitors, and cell surface binding was also detected with S195G CG. Therefore, we propose that the CG-induced aggregation of MCF-7 cells occurs via a 2-step process, in which CG binds to the cell surface, independently of its catalytic site, and then induces cell aggregation, which is dependent on its enzymatic activity.

Từ khóa


Tài liệu tham khảo

2005, Journal of Internal Medicine, 257, 319, 10.1111/j.1365-2796.2005.01476.x

10.1038/nri1841

10.1124/pr.110.002733

10.1016/j.molimm.2009.10.003

1987, Biochemistry, 26, 2289, 10.1021/bi00382a032

10.1016/j.molimm.2010.04.020

10.1158/0008-5472.CAN-10-2583

1975, The Journal of Clinical Investigation, 56, 1118, 10.1172/JCI108186

10.1073/pnas.071057398

10.1074/jbc.M302718200

1988, Biochimica et Biophysica Acta, 948, 175

1997, Cancer, 80, 1529

10.1038/nrc2622

10.1016/S0304-419X(01)00038-5

1973, European Journal of Cancer, 9, 223, 10.1016/S0014-2964(73)80022-2

1976, Cancer Research, 36, 889

2001, Cancer Research, 61, 5231

1976, International Journal of Cancer, 18, 331, 10.1002/ijc.2910180310

10.1016/S0140-6736(00)04046-0

10.1023/A:1015587423262

2003, Cancer Research, 63, 1405

2003, American Journal of Pathology, 163, 2221, 10.1016/S0002-9440(10)63580-8

10.1111/j.1349-7006.2005.00097.x

10.1155/2009/850940

1979, The Journal of Biological Chemistry, 254, 4027, 10.1016/S0021-9258(18)50690-6

10.1128/MCB.23.12.4267-4282.2003

1997, Journal of Leukocyte Biology, 61, 73, 10.1002/jlb.61.1.73

10.1038/35038119

1990, Biochemical Journal, 266, 55, 10.1042/bj2660055

1996, The EMBO Journal, 15, 5481, 10.1002/j.1460-2075.1996.tb00933.x

1994, The Journal of Biological Chemistry, 269, 25219, 10.1016/S0021-9258(17)31520-X

10.1074/jbc.270.21.12912

1990, Proceedings of the National Academy of Sciences of the United States of America, 87, 2304, 10.1073/pnas.87.6.2304

1991, Proceedings of the National Academy of Sciences of the United States of America, 88, 6229, 10.1073/pnas.88.14.6229

1986, The Journal of Immunology, 136, 1061, 10.4049/jimmunol.136.3.1061

1995, Biochemical Journal, 311, 675, 10.1042/bj3110675

10.1038/sj.bjp.0707507

10.1111/j.1476-5381.2010.00705.x

2001, Cancer Research, 61, 5933

10.1016/S0167-4838(98)00085-5

10.1074/jbc.275.10.6819

10.1158/0008-5472.CAN-08-1956

10.1074/jbc.270.40.23437

1995, The Journal of Immunology, 155, 5803, 10.4049/jimmunol.155.12.5803

10.1074/jbc.M608346200

1986, Annals of Clinical Biochemistry, 23, 206, 10.1177/000456328602300212

1989, The Journal of Immunology, 143, 2961, 10.4049/jimmunol.143.9.2961

1989, Blood and Vessel, 20, 13